Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Rhythm Pharmaceuticals Inc shares valued at $1,912,326 were sold by Cramer Pamela J. on Nov 07 ’25. At $98.82 per share, Cramer Pamela J. sold 19,351 shares. The insider’s holdings dropped to 20,814 shares worth approximately $2.04 million following the completion of this transaction.
Also, Cramer Pamela J. sold 3,515 shares, netting a total of over 351,500 in proceeds. Following the sale of shares at $100.00 each, the insider now holds 20,814 shares.
Before that, PAMELA CRAMER had added 3,515 shares to its account. In a trade valued at $352,554, the Officer bought Rhythm Pharmaceuticals Inc shares for $100.30 each.
As published in a research note from Oppenheimer on November 05, 2025, Rhythm Pharmaceuticals Inc [RYTM] has been rated down from an Outperform to a Perform. Analysts at Goldman started covering the stock with ‘”a Buy”‘ outlook in a report released in early July. As of July 07, 2025, Leerink Partners has initiated its “an Outperform” rating for RYTM. Earlier on April 07, 2025, BofA Securities upgraded its rating. Their new recommendation was “a Buy” for RYTM stock which previously was a “a Neutral”.
Analyzing RYTM Stock Performance
On last trading session, Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] plunged -1.94% to $97.92. The stock’s lowest price that day was $97.77, but it reached a high of $102.7 in the same session. During the last five days, there has been a drop of approximately -1.56%. Over the course of the year, Rhythm Pharmaceuticals Inc shares have jumped approximately 45.43%. Shares of the company reached a 52-week high of $116.00 on 10/30/25 and a 52-week low of $45.90 on 04/07/25.
Support And Resistance Levels for Rhythm Pharmaceuticals Inc (RYTM)
According to the 24-hour chart, there is a support level at 96.23, which, if violated, would cause prices to drop to 94.53. In the upper region, resistance lies at 101.16. The next price resistance is at 104.39. RSI (Relative Strength Index) is 39.11 on the 14-day chart, showing neutral technical sentiment.
Is Rhythm Pharmaceuticals Inc subject to short interest?
Stocks of Rhythm Pharmaceuticals Inc saw a sharp steep in short interest on 2025-10-31 dropping by -0.35 million shares to 5.23 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 5.58 million shares. A decline of -6.65% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.4 of the overall float, the days-to-cover ratio (short ratio) decline to 9.4.
Which companies own the most shares of Rhythm Pharmaceuticals Inc (RYTM)?
In terms of Rhythm Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 129 in the next 12 months, up nearly 29.18% from the previous closing price of $99.86. Analysts anticipate Rhythm Pharmaceuticals Inc stock to reach 142 by 2025, with the lowest price target being 110. In spite of this, 5 analysts ranked Rhythm Pharmaceuticals Inc stock as Buy at the end of 2025. On March 05, 2025, Stifel assigned a price target of “a Buy” to the stock and resumed coverage with a $78.
